Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 13 EP applications Robert Wild has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12190855

Method for preparation of a high concentration liquid formulation of an antibody

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
APPLICATION WITHDRAWN
EP12190793

Cross-flow ultrafiltration device and method for concentration of pharmaceutical compositions

IPC classification:
B01D 61/14, B01D 63/08
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
APPLICATION WITHDRAWN
EP12190838

Vent gases for use in drying, storing and/or reconstituting biomolecules

IPC classification:
A61K 9/19, A61K 38/00, A61K 39/00, A61K 47/18, A61K 47/26, B65B 31/00, C07K 16/28, F26B 5/06
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
APPLICATION WITHDRAWN
EP14164018

3,4,4a,10b-tetrahydro-1H-thiopyrano-[4,3-c]isoquinoline derivatives

IPC classification:
A61K 31/519, A61P 11/00, A61P 11/06, A61P 11/08, C07D 519/00
Applicant:
AstraZeneca AB
Applicant:
Takeda GmbH
Agent:
Tracy Anne Burns, AstraZeneca PLC
Agent:
Robert Wild, Takeda GmbH
Status:
PATENT GRANTED
EP12728453

NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES

IPC classification:
A61K 31/519, A61P 11/00, C07D 487/04
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12729458

NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C]ISOQUINOLINE COMPOUNDS

IPC classification:
A61K 31/519, A61P 11/00, C07D 495/04, C07D 519/00
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13724745

NOVEL EP2 RECEPTOR AGONISTS

IPC classification:
C07C 233/64, C07C 233/75
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
EXAMINATION REQUESTED
EP12196702

Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

IPC classification:
A61K 31/473, A61P 3/10, A61P 11/00, A61P 11/06, A61P 17/00, A61P 17/06, C07D 401/04
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13791947

METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
GRANT OF PATENT INTENDED
EP14710314

FORMULATION OF AN ANTIBODY AND USE THEREOF

IPC classification:
C07K 16/28
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
EXAMINATION REQUESTED
EP11741221

DEVICE AND SYSTEM FOR DELIVERY OF AN AEROSOL TO A PATIENT ON VENTILATORY SUPPORT

IPC classification:
A61M 16/06, A61M 16/14
Applicant:
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
Applicant:
Takeda GmbH
Agent:
Herzog Fiesser & Partner Patentanwälte PartG mbB
Agent:
Robert Wild, Takeda GmbH
Status:
GRANT OF PATENT INTENDED
EP15700703

TREATMENT OF PARTLY CONTROLLED OR UNCONTROLLED SEVERE ASTHMA WITH A PDE4 INHIBITOR (AND IN COMBINATION WITH A LEUKOTRIENE MODIFIER)

IPC classification:
A61K 31/47, A61K 31/473, A61K 45/06, A61P 11/06
Applicant:
Takeda GmbH
Agent:
Robert Wild, Takeda GmbH
Status:
EXAMINATION REQUESTED
EP15708411

UTI FUSION PROTEINS

IPC classification:
A61K 38/17, C07K 14/81
Applicant:
Takeda GmbH
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Robert Wild, Takeda GmbH
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature